Global opioid use has remained broadly stable, with strong regional differences in prevalence of use.The number of people who use opioids worldwide has remained relatively stable in the last five years, with the estimate for 2024 only slightly higher than the level in 2019.Prevalence of past-year…
Global opiate use has remained broadly stable, with slight declines in the prevalence of use.The number of people using opiates worldwide has remained stable over the last five years, while the annual prevalence of use declined slightly from 0.61 per cent in 2020 to 0.57 per cent in 2023 and 2024.…
The illicit ketamine market has expanded beyond Asia, with rising use and emerging harms in new regions.Once concentrated in East and South-East Asia, several countries with time-series data (for example, the United Kingdom, Australia or the United States) have recorded an increase in the use of…
The type of opioid that is most used non-medically varies across regions and countries.With the highest population globally, Asia is also the region with the highest number of people who use opioids.The type of opioid used differs across regions, with opiates such as heroin dominating in Asia and…
The non-medical use and trafficking of tramadol remain most concentrated in North Africa, West and Central Africa, and the Near and Middle East and South-West Asia, though there remains significant localized non-medical use in other regions.There remains a significant data gap on tramadol use and…
Similarly to most internationally controlled drugs, the use of NPS among adolescents is higher than among the general population, but the difference between adolescent boys and girlsis lower for NPS than for controlled drugs.Limited data suggest that NPS use is generally higher among school…
The health harms posed by the non-medical use of opioids remains high in North America, but have started to decline in late 2023 and in 2024.Opioid overdose deaths reached historical highs in the United States of America and Canada between 2021 and 2023 but have since started to decline, returning…
Opioid-related harms, measured as new people entering treatment, have declined in Europe.Although the share of people in treatment for opioid use disorders remains substantial in Europe, the number of people entering treatment for the first time has decreased.In Eastern Europe and South-Eastern…
In East and South-East Asia, limited regular data collection makes it difficult to assess long-term trends in opioid use. However, data on people registered for drug use and people in drug treatment indicate a decline in opioid (mainly heroin) use over the past 10 to 15 years.In most of East and…
Fentanyls continue to account for the largest share of harm from the non-medical use of NPS synthetic opioids, in particular in North America, but the arrival on the market of nitazenes and orphines , which are often more potent than fentanyls, has led to a number of acute emergencies and fatal…
Limited data suggest stable or declining NPS use among young people, with some exceptions.Time-series data on NPS use among young people are scarce and largely limited to high-income countries.Where data are available, the use of NPS is generally stable or declining, as corroborated by recent…
Globally, the use of synthetic NPS continues to be lower than most internationally controlled drugs.Based on the available data – mainly from high-income countries – the use of synthetic NPS is generally lower than the use of drugs under international control. By contrast, the scarce data on plant-…
